TVRD Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
7.1M
-7.1%
7.6M
+27.8%
5.9M
-33.0%
8.9M
R&D
4.9M
-10.6%
5.5M
+52.4%
3.6M
-37.9%
5.8M
SG&A
2.1M
+2.1%
2.1M
-10.2%
2.3M
-23.8%
3.1M
Operating Income
-7051000
+7.1%
-7587000
-27.8%
-5938000
+33.0%
-8869000
EBITDA
-7027000
+7.1%
-7563000
-27.9%
-5914000
+33.0%
-8822000
Net Income
-6804000
+6.5%
-7275000
-31.6%
-5527000
-232.6%
4.2M
EPS (Basic)
$-0.73
+5.2%
$-0.77
-30.5%
$-0.59
-215.7%
$0.51
EPS (Diluted)
$-0.73
-7.4%
$-0.68
-15.3%
$-0.59
+41.0%
$-1.00
Shares (Diluted)
9.4M
-12.5%
10.7M
+14.4%
9.4M
+10.9%
8.5M
Tvardi Therapeutics (TVRD) โ€” Financials